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Methods. We employed a retrospective cohort design and data from a large US healthcare claims repository. The study population included all adults aged ≥18 years who had ≥1 day of health benefits at any time from 2007-2015, and who met minimum criteria for characterizing comorbidity profiles. Study subjects were stratified by age (18-49, 50-64, and ≥65 years) and risk profile ("at-risk", "high-risk", and "healthy") based on ACIP-identified indications for pneumococcal vaccination. Episodes of IPD were identified in each year of the study period, and rate ratios comparing IPD incidence in persons with at-risk and high-risk conditions, respectively, vs. healthy persons, were computed.
Results. A substantial decline in IPD was observed in 2013-2015 compared with 2007-2010 in healthy, at-risk, and high-risk adults in all age groups. However, the proportional decline was lower in those with high-risk and at-risk conditions, resulting in an increased rate ratio for adults with comorbid conditions (Table) . Conclusion. IPD burden declined from the pre-PCV13 era. This decline was greatest in healthy adults (vs.. those with at-risk or high-risk conditions); adults with comorbid conditions, especially those ≥65 years old, appear to have benefited least from the direct and indirect impacts of PCV13 immunization. Greater understanding as to which serotypes cause disease in adults with comorbid conditions and which host factors in individuals predispose to IPD is needed to develop additional prevention strategies for high-risk groups.
Disclosures A pneumococcal polysaccharide vaccine (PPSV23) has been available for use in adults ≥65 years old since 1983 with vaccination rates of ~65% in the past decade. A conjugate vaccine (PCV13) has been recommended for adults since 2014, and for children since 2010 (replaced PCV7 which was used since 2000). The serotype distribution of pneumococci causing infections in adult patients in the US was evaluated.
Methods. 6,491 S. pneumoniae isolates were collected from patients (≥18 years old) seen/hospitalized in 105 US centers and recovered primarily (77.8%; 5,052/6,491) from lower respiratory tract specimens. Identification was performed by biochemical algorithms and/or PCR. The cpsB sequence was obtained by PCR or next genome sequencing for serotype determination. Multiplex PCR and/or Quellung reaction were performed, as needed.
Results. 19F was the most prevalent PCV7 serotypes with annual rates of 1.6-3.1%, but no trends were observed for this serotype during the period. Overall, PCV13 serotype prevalence declined considerably from 38.6% in 2009 to 23.1% in 2016, but rates remained stable during 2013-2016 (21.5-24.6%). Serotype 19A (12.4%) and 3 (9.1%) were the most common PCV13 serotypes (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) , followed by 7F (2.4%). Prevalence of 19A and 7F declined from 17.5% to 7.1% and from 4.6% to 0.7%, respectively, while the prevalence of serotype 3 remained stable. The proportion of non-vaccine serotypes increased, as did PPSV23 (non-PCV13). Among non-vaccine serotypes, 35B (8.1%), 23A (6.2%), and 6C/6D (5.8%) were the most common, followed by 23B (4.8%) and 15A/15F (4.8%). Prevalence of serotype 35B (from 3.9% to 12.6%) and 23B (from 3.7% to 7.8%) increased considerably during the study period. Serotypes 23A and 15A/15F remained stable throughout; however, serotype 6C/6D decreased from 7.6% to 3.4%.
Conclusion. Prevalence of serotype 19F remained low and stable during the study period. PCV13 serotypes declined considerably, but serotypes 19A and 3 remained elevated. The consistent increase of non-vaccine serotypes, especially 35B, may be a reason for concern since it exhibits decreased susceptibility to β-lactams. Continued surveillance is needed to constantly assess the dynamic changes of serotypes affecting the adult US population. Friday, October 6, 2017: 12:30 PM Background. In the fall of 2014, the Advisory Committee on Immunization Practices (ACIP) recommended 13-valent pneumococcal conjugate vaccine (PCV13) for all US adults age ≥65 years. Coverage rates are currently unknown. This study estimated overall PCV13 coverage rates in older adults and determined if disparities in uptake existed for some sociodemographic groups.
Disclosures
Methods. A monthly series (August 1, 2014 -Feb 28, 2017) of cross-sectional analyses of administrative diagnosis and prescription claims data collected by QuintilesIMS and linked to sociodemographic data collected by Experian were used to estimate overall and subpopulation-level uptake of PCV13 among US adults age ≥65. Uptake estimates were adjusted to PCV13 manufacturer sales data to account for missingness patterns in QuintilesIMS claims data. Univariate and multivariable analyses of PCV13 uptake were performed across sociodemographic factors (e.g., race/ethnicity, household income, neighborhood urbanicity, education status).
Results. Among adults age ≥65, 50% received PCV13 by the end of February 2017. Disparities in PCV13 uptake were apparent. Black adults (39%) and Hispanics (32%) (vs. 53% for whites), the poor (36% vs. 64% for lowest vs. highest income deciles), adults with low educational status (37% vs. 58% for those without high school education vs. college educated), and those living in rural (33%) or urban/inner city (41%) areas (vs. 52% in suburban areas) had significantly lower PCV13 uptake (all P < .001) (Figure) . These differences persisted in multivariable analyses.
Conclusion. PCV13 uptake among adults age ≥65 occurred rapidly after ACIP recommendation in late 2014. Yet, poor and minority communities, rural and urban/ inner city areas, and communities with low educational attainment may need more time to adequately implement adult vaccine guidelines following ACIP recommendation. In 2018, current adult pneumococcal recommendations will be revisited by ACIP.
